C2orf42

Across TCGA pan-cancer cohorts, C2orf42 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C2orf42 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C2orf42 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C2orf42 expression acts as an unfavorable survival marker.

LIHC, BLCA, and ESCA are the cancer types where C2orf42 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.172	0.779	<.001	27	view →
BLCA	DFS	Median	All	0.187	0.627	.005	12	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C2orf42–LIHC (OS)

Open the LIHC breakdown →